Amid complaints from shareholder activists, Endo International (ENDP) has issued a report about the risks of selling opioid painkillers and agreed to expand a so-called clawback policy for executive compensation when negligence occurs. The company will also beef up disclosure of its lobbying efforts.
The move is the latest victory for Investors for Opioid Accountability, a coalition of institutional investors that has been pushing drug makers, wholesalers, and pharmacies to take steps to rein in the opioid crisis by changing business practices. Previously, Assertio Therapeutics (ASRT) agreed to monitor opioid risks, but Endo is the first large drug maker to take a more comprehensive step.
About the Author Reprints
